TILRAY BRANDS INC (TLRY.CA) Stock Fundamental Analysis
Canada - TSX:TLRY - US88688T1007 - Common Stock
1.74 CAD
+0.05 (+2.96%)
TLRY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 31 industry peers in the Pharmaceuticals industry. TLRY has a bad profitability rating. Also its financial health evaluation is rather negative. TLRY is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TLRY has reported negative net income.
TLRY had a negative operating cash flow in the past year.
TLRY had negative earnings in each of the past 5 years.
In the past 5 years TLRY reported 4 times negative operating cash flow.
1.2 Ratios
TLRY's Return On Assets of -105.42% is on the low side compared to the rest of the industry. TLRY is outperformed by 83.87% of its industry peers.
Looking at the Return On Equity, with a value of -144.68%, TLRY is doing worse than 77.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.42% | ||
| ROE | -144.68% | ||
| ROIC | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 29.29%, TLRY is in line with its industry, outperforming 45.16% of the companies in the same industry.
In the last couple of years the Gross Margin of TLRY has grown nicely.
The Profit Margin and Operating Margin are not available for TLRY so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLRY has been increased compared to 1 year ago.
Compared to 5 years ago, TLRY has more shares outstanding
TLRY has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.33, we must say that TLRY is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.33, TLRY is in line with its industry, outperforming 41.94% of the companies in the same industry.
TLRY has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TLRY (0.19) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.33 |
ROIC/WACCN/A
WACC7.81%
2.3 Liquidity
A Current Ratio of 2.46 indicates that TLRY has no problem at all paying its short term obligations.
The Current ratio of TLRY (2.46) is comparable to the rest of the industry.
TLRY has a Quick Ratio of 1.49. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
TLRY has a Quick ratio of 1.49. This is in the better half of the industry: TLRY outperforms 61.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.46 | ||
| Quick Ratio | 1.49 |
3. Growth
3.1 Past
The earnings per share for TLRY have decreased strongly by -648.00% in the last year.
TLRY shows a small growth in Revenue. In the last year, the Revenue has grown by 4.10%.
Measured over the past years, TLRY shows a very strong growth in Revenue. The Revenue has been growing by 37.52% on average per year.
EPS 1Y (TTM)-648%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)4.1%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
3.2 Future
TLRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.44% yearly.
Based on estimates for the next years, TLRY will show a small growth in Revenue. The Revenue will grow by 4.31% on average per year.
EPS Next Y97.21%
EPS Next 2Y40.83%
EPS Next 3Y26.48%
EPS Next 5Y15.44%
Revenue Next Year3.68%
Revenue Next 2Y4.08%
Revenue Next 3Y4.04%
Revenue Next 5Y4.31%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
TLRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLRY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TLRY is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 54.11 |
4.3 Compensation for Growth
A more expensive valuation may be justified as TLRY's earnings are expected to grow with 26.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.83%
EPS Next 3Y26.48%
5. Dividend
5.1 Amount
No dividends for TLRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:TLRY (11/7/2025, 7:00:00 PM)
1.74
+0.05 (+2.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners9.86%
Inst Owner ChangeN/A
Ins Owners0.36%
Ins Owner ChangeN/A
Market Cap1.95B
Revenue(TTM)821.31M
Net Income(TTM)-2.19B
Analysts71.25
Price Target2.64 (51.72%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2749.13%
Min EPS beat(2)-5362.97%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-1413.07%
Min EPS beat(4)-5362.97%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-730.51%
EPS beat(12)1
Avg EPS beat(12)-762.79%
EPS beat(16)3
Avg EPS beat(16)-613.4%
Revenue beat(2)0
Avg Revenue beat(2)-10.25%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-7.23%
Revenue beat(4)0
Avg Revenue beat(4)-8.93%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-4.66%
Revenue beat(8)0
Avg Revenue beat(8)-5.77%
Revenue beat(12)1
Avg Revenue beat(12)-3.93%
Revenue beat(16)1
Avg Revenue beat(16)-4.24%
PT rev (1m)82.5%
PT rev (3m)105.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.71%
EPS NY rev (1m)61.11%
EPS NY rev (3m)77.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)0.62%
Revenue NY rev (3m)-1.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.69 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.92 | ||
| P/tB | 1.88 | ||
| EV/EBITDA | 54.11 |
EPS(TTM)-2.11
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS1.03
BVpS1.9
TBVpS0.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.42% | ||
| ROE | -144.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.29% | ||
| FCFM | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
F-Score4
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 11.15 | ||
| Cap/Depr | 24.66% | ||
| Cap/Sales | 4.01% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.46 | ||
| Quick Ratio | 1.49 | ||
| Altman-Z | -1.33 |
F-Score4
WACC7.81%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.01%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-648%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y97.21%
EPS Next 2Y40.83%
EPS Next 3Y26.48%
EPS Next 5Y15.44%
Revenue 1Y (TTM)4.1%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
Revenue Next Year3.68%
Revenue Next 2Y4.08%
Revenue Next 3Y4.04%
Revenue Next 5Y4.31%
EBIT growth 1Y-11.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.7%
EBIT Next 3Y29.32%
EBIT Next 5Y17.43%
FCF growth 1Y-111.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-206.1%
OCF growth 3YN/A
OCF growth 5YN/A
TILRAY BRANDS INC / TLRY.CA FAQ
Can you provide the ChartMill fundamental rating for TILRAY BRANDS INC?
ChartMill assigns a fundamental rating of 2 / 10 to TLRY.CA.
What is the valuation status of TILRAY BRANDS INC (TLRY.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to TILRAY BRANDS INC (TLRY.CA). This can be considered as Overvalued.
How profitable is TILRAY BRANDS INC (TLRY.CA) stock?
TILRAY BRANDS INC (TLRY.CA) has a profitability rating of 1 / 10.
How financially healthy is TILRAY BRANDS INC?
The financial health rating of TILRAY BRANDS INC (TLRY.CA) is 3 / 10.